Since 1995, Equinox Group has provided analytics to support R&D decisions to biopharmaceutical companies, assessing the potential for drugs from discovery to launch, and anywhere in between.
what we do
Equinox Group specializes in predicting the commercial performance of drug programs in all stages of research and development, quantifying the potential for:
We have evaluated thousands of drug profiles across hundreds of indications in oncology, immunology, rare diseases, cardio-metabolic disorders, infectious diseases, neurology, respiratory, urology, ophthalmology, and endocrine disorders. We also have tailored methods to solve the unique analytical challenges that arise in oncology and rare diseases.
Our analytical methods have helped clients around the world solve problems at all stages of R&D. Want to know more about how we can help you? Check out our tools here.